Mark A Espeland1, Gareth R Dutton2, Rebecca H Neiberg1, Owen Carmichael3, Kathleen M Hayden4, Karen C Johnson5, Robert W Jeffery6, Laura D Baker4,7, Delilah R Cook1, Dalane W Kitzman7, Stephen R Rapp4,8. 1. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina. 2. Division of Preventive Medicine, University of Alabama at Birmingham. 3. Institute for Dementia Research and Prevention, Pennington Biomedical Research Center, Baton Rouge, Los Angeles. 4. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina. 5. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis. 6. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis. 7. Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina. 8. Department of Psychiatry and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Abstract
Background: Lifestyle interventions to reduce weight and increase activity may preserve higher-order cognitive abilities in overweight/obese adults with type 2 diabetes (T2D). Methods: Adults (N = 5,084) with T2D who enrolled in a randomized clinical trial of a 10-year intensive lifestyle intervention (ILI) compared with diabetes support and education were queried at baseline and repeatedly during follow-up for complaints about difficulties in memory, problem-solving, and decision-making abilities. Results: For those without baseline complaints, assignment to ILI was associated with lower odds that complaints would emerge during follow-up for decision-making ability (odds ratio [OR]=0.851, [95% CI, 0.748,0.967], p=0.014), and, among individuals who were not obese, lower odds that complaints would emerge about problem-solving ability (OR=0.694 [0.510,0.946]). No cognitive benefits from ILI were seen for individuals with baseline complaints about cognitive abilities. ILI may have exacerbated the severity of complaints about problem-solving ability during follow-up among individuals with baseline complaints and cardiovascular disease (OR=2.949 [1.378,6.311]). Conclusions: A long-term multidomain ILI may reduce the likelihood that complaints about difficulties in higher-order cognitive abilities will emerge in T2D adults without pre-existing complaints. Among those with pre-existing complaints, the ILI did not prevent increases in complaint severity.
Background: Lifestyle interventions to reduce weight and increase activity may preserve higher-order cognitive abilities in overweight/obese adults with type 2 diabetes (T2D). Methods: Adults (N = 5,084) with T2D who enrolled in a randomized clinical trial of a 10-year intensive lifestyle intervention (ILI) compared with diabetes support and education were queried at baseline and repeatedly during follow-up for complaints about difficulties in memory, problem-solving, and decision-making abilities. Results: For those without baseline complaints, assignment to ILI was associated with lower odds that complaints would emerge during follow-up for decision-making ability (odds ratio [OR]=0.851, [95% CI, 0.748,0.967], p=0.014), and, among individuals who were not obese, lower odds that complaints would emerge about problem-solving ability (OR=0.694 [0.510,0.946]). No cognitive benefits from ILI were seen for individuals with baseline complaints about cognitive abilities. ILI may have exacerbated the severity of complaints about problem-solving ability during follow-up among individuals with baseline complaints and cardiovascular disease (OR=2.949 [1.378,6.311]). Conclusions: A long-term multidomain ILI may reduce the likelihood that complaints about difficulties in higher-order cognitive abilities will emerge in T2D adults without pre-existing complaints. Among those with pre-existing complaints, the ILI did not prevent increases in complaint severity.
Authors: Stephen R Rapp; Jose A Luchsinger; Laura D Baker; George L Blackburn; Helen P Hazuda; Kathryn E Demos-McDermott; Robert W Jeffery; Jeffrey N Keller; Jeanne M McCaffery; Nicholas M Pajewski; Mary Evans; Thomas A Wadden; Steven E Arnold; Mark A Espeland Journal: J Am Geriatr Soc Date: 2017-01-09 Impact factor: 5.562
Authors: Mark A Espeland; Stephen R Rapp; George A Bray; Denise K Houston; Karen C Johnson; Abbas E Kitabchi; Andrea L Hergenroeder; Jeff Williamson; John M Jakicic; Brent van Dorsten; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2014-03-11 Impact factor: 6.053
Authors: A J Saykin; H A Wishart; L A Rabin; R B Santulli; L A Flashman; J D West; T L McHugh; A C Mamourian Journal: Neurology Date: 2006-09-12 Impact factor: 9.910
Authors: Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski Journal: N Engl J Med Date: 2013-06-24 Impact factor: 91.245
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Mark A Espeland; José A Luchsinger; Laura D Baker; Rebecca Neiberg; Steven E Kahn; Steven E Arnold; Rena R Wing; George L Blackburn; George Bray; Mary Evans; Helen P Hazuda; Robert W Jeffery; Valerie M Wilson; Jeanne M Clark; Mace Coday; Kathryn Demos-McDermott; John P Foreyt; Frank Greenway; James O Hill; Edward S Horton; John M Jakicic; Karen C Johnson; William C Knowler; Cora E Lewis; David M Nathan; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; Thomas A Wadden; Stephen R Rapp Journal: Neurology Date: 2017-04-26 Impact factor: 9.910
Authors: Mark A Espeland; Jose A Luchsinger; Rebecca H Neiberg; Owen Carmichael; Paul J Laurienti; Xavier Pi-Sunyer; Rena R Wing; Delilah Cook; Edward Horton; Ramon Casanova; Kirk Erickson; R Nick Bryan Journal: J Am Geriatr Soc Date: 2017-10-30 Impact factor: 5.562
Authors: Mark A Espeland; Kasia Lipska; Michael E Miller; Julia Rushing; Ronald A Cohen; Joseph Verghese; Mary M McDermott; Abby C King; Elsa S Strotmeyer; Steven N Blair; Marco Pahor; Kieran Reid; Jamehl Demons; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2017-06-01 Impact factor: 6.053
Authors: Kathleen M Hayden; Rebecca H Neiberg; Joni K Evans; José A Luchsinger; Owen Carmichael; Gareth R Dutton; Karen C Johnson; Steven E Kahn; Stephen R Rapp; Sevil Yasar; Mark A Espeland Journal: Dement Geriatr Cogn Disord Date: 2021-08-19 Impact factor: 3.346
Authors: Felicia R Simpson; Nicholas M Pajewski; Barbara Nicklas; Stephen Kritchevsky; Alain Bertoni; Frank Ingram; Daniel Ojeranti; Mark A Espeland Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-25 Impact factor: 6.053
Authors: Hussein N Yassine; Andrea Anderson; Roberta Brinton; Owen Carmichael; Mark A Espeland; Siobhan Hoscheidt; Christina E Hugenschmidt; Jeffrey N Keller; Anne Peters; Xavier Pi-Sunyer Journal: Neurobiol Aging Date: 2020-04-08 Impact factor: 4.673
Authors: Felicia R Simpson; Owen Carmichael; Kathleen M Hayden; Christina E Hugenschmidt; Jeanne M McCaffery; Sevil Yasar; Nicholas M Pajewski; Mark A Espeland Journal: J Diabetes Complications Date: 2021-03-16 Impact factor: 3.219
Authors: Mark A Espeland; Joni K Evans; Owen Carmichael; Jose A Luchsinger; Santica M Marcovina; Rebecca Neiberg; Karen C Johnson; Steven E Kahn; Kathleen M Hayden Journal: Obesity (Silver Spring) Date: 2022-08-03 Impact factor: 9.298